Lung cancer continues to be a major cause of cancer related death globally. Therapies targeting driver mutations have significantly extended the survival of patients whose lung cancer cells harbor these mutations. Patients with KRAS mutations, however, lacked specific targeted therapy until the recent FDA approval of sotorasib, a specific inhibitor of KRAS G12C mutant protein. We will discuss the efficacy and toxicities of the novel KRAS G12C inhibitors as well as other indirect strategies for targeting oncogenic KRAS mutations. We will review the limited literature on acquired resistance to these inhibitors and the novel combinatorial treatment strategies that are being tested currently in clinical trials.

Original languageEnglish
Pages (from-to)28-33
Number of pages6
JournalLung Cancer
StatePublished - Mar 2022


  • KRAS G12C
  • Lung adenocarcinoma
  • Lung cancer
  • Targeted therapies


Dive into the research topics of 'Targeting KRAS G12C mutation in lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this